Depomed Issues Statement in Response to Starboard Value LP 13D Filing

NEWARK, Calif., April 8, 2016  -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today issued the following statement in response to the Schedule 13D filed April 7 with the Securities and Exchange Commission by Starboard Value LP ("Starboard"):
 
Depomed welcomes open communications with its shareholders and values constructive input toward the goal of enhancing shareholder value. Depomed notes that Starboard has not communicated with the Company prior to filing the 13D and has not attempted to hold any discussions with the Company. Depomed's Board and management are committed to creating value for all Depomed shareholders. 
Published: 08 April 2016
Written by Editor
Nasdaq   Up on News  
Read more: Depomed Inc ( DEPO )

Akorn Provides Preliminary Unaudited Full Year 2015 Financial Results and Issues 2016 Financial Guidance

 - Preliminary 2015 GAAP Revenue of $985 Million -
- Preliminary 2015 GAAP EPS of $1.14; Preliminary Adjusted 2015 EPS of $1.93 -
- GAAP Revenue of $1.06 - $1.08 Billion Expected in 2016 -
- Adjusted EPS of $2.10 - $2.20 Expected in 2016; GAAP EPS of $1.56 - $1.66 -
- Conference Call and Webcast to Be Held At 10:00 a.m. EDT Today -
 
LAKE FOREST, Ill., March 22, 2016 -- Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today provided preliminary unaudited 2015 financial results and issued 2016 financial guidance. Akorn also provided material updates on several other important business items.
 
Preliminary net revenue for 2015 is anticipated to be approximately $985 million and preliminary GAAP diluted earnings per share (EPS) is expected to be $1.14. Preliminary non-GAAP adjusted EPS for 2015 is expected to be $1.93.
Published: 22 March 2016
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Akorn Inc ( AKRX )

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights

Positive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway
FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome
Three ZYN002 Phase 2a Trials Planned for Initiation in Second Half 2016
 
DEVON, Pa., March 14, 2016  -- Zynerba Pharmaceuticals, Inc. (ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter and year ended December 31, 2015, and provided an overview of recent operational highlights.
 
“We are making significant progress in advancing our pipeline of first-in-class transdermal cannabinoid treatments.  
Published: 14 March 2016
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Zynerba Pharmaceuticals Inc ( ZYNE )

Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016

Clinical Data Support Cardiac Safety of EVK-001

SOLANA BEACH, Calif., Feb. 17, 2016 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company’s successful thorough electrocardiogram (ECG) study of EVK-001, its metoclopramide nasal spray product candidate, were accepted for presentation at Digestive Disease Week 2016. As previously announced, this thorough ECG study demonstrated that EVK-001 did not prolong the cardiac QT and corrected QT (QTc) intervals in healthy subjects across a range of plasma concentrations.

Evoke designed the study in accordance with published FDA and ICH guidance on the clinical evaluation of QT/QTc interval prolongation and the proarrhythmic potential of non-cardiac drugs. The QT interval represents the amount of time the heart's electrical system takes to repolarize, or recharge, after each beat, and prolongation of the interval may increase the risk for cardiac arrhythmias.

Published: 17 February 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Evoke Pharma Inc ( EVOK )

AMAG Pharmaceuticals Announces Preliminary 2015 Financial Results and Provides 2016 Financial Guidance

  • Achieves record 2015 annual Feraheme® and Makena® product sales: Makena grows  approximately 52% over 2014
  • Two maternal health transactions in 2015 to bolster future revenue growth and sustainability
  • Company guides to approximately $545 million and $270 million in 2016 revenue and adjusted EBITDA1

WALTHAM, Mass., Jan. 11, 2016  -- AMAG Pharmaceuticals, Inc. (AMAG) today provided a business update, announced preliminary unaudited fourth quarter and annual 2015 financial results and provided 2016 financial guidance. The company will present further details at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 10:00 a.m. Pacific time.

Published: 11 January 2016
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: AMAG Pharmaceuticals Inc ( AMAG )
  1. MYOS Corporation ( MYOS )
  2. Pacira Pharmaceuticals Inc ( PCRX )
  3. TherapeuticsMD Inc ( TXMD )
  4. Oramed Pharmaceuticals Inc ( ORMP )
  5. SciClone Pharmaceuticals Inc ( SCLN )

Videos / Webinars

View all videos